A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination Therapy.
Chin-Chou WangLi-Chung ChiuPi-Hung TungScott Chih-Hsi KuoChia-Hsun ChuAllen Chung-Cheng HuangChih-Liang WangChih-Hung ChenCheng-Ta YangPing-Chih HsuPublished in: Oncology and therapy (2021)
Erlotinib combined with bevacizumab is an effective and safe therapy for untreated metastatic EGFR-mutated lung adenocarcinoma. The combination does not alter secondary EGFR-T790M mutations in patients with acquired resistance and is feasible in real-world clinical practice.